Non-Aneurysmal Perimesencephalic Subarachnoid Hemorrhage: A Literature Review

Abstract

Spontaneous non-aneurysmal subarachnoid haemorrhage (NAPMSAH) (addressing point 1) is a relatively rare occurrence in clinical settings as it is rarely misdiagnosed and usually involves a significantly better prognosis than the classical aneurysmal pattern. We hereby focused on a comprehensive analysis of this distinct pathological entity with the purpose of analysing possible pathophysiological entities, outcomes and treatment options involving this diagnosis with a focus on demographical, epidemiological and clinical data. The clinical setting includes focal neurological signs related to the anatomical structures, while computer tomography followed by tomographic angiography are the most common diagnosis tools, with a typical hyperdense lesion involving the midbrain, fourth ventricle and subthalamic areas without an angiographic correspondent, such as an aneurysmal pathology. Further investigations can also be used to highlight this diagnosis, such as interventional angiography or magnetic resonance imaging. Given the rarity of this condition and its relatively better prognosis, treatment options usually remain conservative. In the present review, the main characteristics of NAPMSAH are discussed.

Comment on Roman-Filip et al. Non-Aneurysmal Perimesencephalic Subarachnoid Hemorrhage: A Literature Review. Diagnostics 2023, 13, 1195

“…We would like to congratulate Roman-Filip et al on their recent review on perimesencephalic hemorrhages [1]. We have a few comments about the diagnostic approach to perimesencephalic hemorrhages.…”

Cervical Artery Dissections—A Demographical Analysis of Risk Factors, Clinical Characteristics Treatment Procedures, and Outcomes—A Single Centre Study of 54 Consecutive Cases

“…Moreover, rupture of the vessel wall carries a risk of vasospasm with short-term complications of CAD, quite like those of subarachnoid hemorrhage [43]. These complications should also be treated accordingly as they provide significant morbidity.…”